A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia. [electronic resource]
Producer: 20030303Description: 35-44 p. digitalISSN:- 0145-2126
- Acute Disease
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Blast Crisis -- drug therapy
- Bone Marrow -- enzymology
- Chemical and Drug Induced Liver Injury -- etiology
- DNA Topoisomerases, Type II -- biosynthesis
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Enzyme Induction -- drug effects
- Enzyme Inhibitors -- administration & dosage
- Etoposide -- administration & dosage
- Female
- Gastrointestinal Diseases -- chemically induced
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Leukemia, Myeloid -- drug therapy
- Male
- Middle Aged
- Neoplasm Proteins -- antagonists & inhibitors
- Neoplasms, Second Primary -- drug therapy
- Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Recurrence
- Remission Induction
- Salvage Therapy
- Topoisomerase I Inhibitors
- Topotecan -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.